Supreme Court Mandates Grievance Redressal for Misleading Medical Ads: States and UTs Face 2-Month Deadline

In a significant move to protect public health and curb deceptive advertising practices, the Supreme Court of India has directed all states and union territories to establish robust grievance redressal mechanisms for complaints against misleading medical advertisements. The apex court, recognizing the potential for "great harm to society" from such deceptive promotions, has set a stringent two-month deadline for these mechanisms to be operational. This directive comes as part of an ongoing case highlighting the rampant issue of misinformation, particularly within the medical and health sectors.

Two-Month Deadline for Grievance Mechanisms

A bench comprising Justices Abhay S Oka and Ujjal Bhuyan issued the order, emphasizing the urgent need for effective implementation of the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. The Court underscored that despite being over seven decades old, the Act has not been enforced in its "true letter and spirit." To rectify this, the states and UTs are now mandated to create accessible grievance redressal pathways for the public to lodge complaints regarding advertisements that violate the 1954 Act.

"We direct the state governments to create proper grievance redressal mechanisms within a period of two months from today and give adequate publicity to the availability at frequent intervals," the bench declared. The Court further specified that these mechanisms should be designed for ease of access, suggesting options like toll-free numbers and email addresses for complaint registration.

Sensitizing Police and Authorizing Enforcement Officers

Beyond establishing complaint channels, the Supreme Court has also instructed states and UTs to actively sensitize their police forces on the provisions of the Drugs and Magic Remedies Act. This directive aims to ensure that law enforcement agencies are well-versed in identifying and acting upon violations related to misleading medical advertisements.

Furthermore, within one month, states and UTs are required to designate an adequate number of gazetted officers empowered under Section 8 of the Act. These authorized officers will possess the critical powers of search and seizure necessary to effectively address instances of prohibited advertising. The Court clarified that upon receiving complaints, whether through the newly established grievance mechanisms or other means, these complaints must be immediately forwarded to the designated officers for prompt action.

The judgment outlines a clear protocol for officers who identify violations. "If the officer finds that there is a contravention of the 1954 Act, he will set the criminal law in motion by lodging a complaint with the police station so that first information reports can be registered," the order stated. This sets the stage for potential criminal proceedings against those found engaging in misleading medical advertising.

Central Dashboard and NALSA Involvement

Acknowledging the need for centralized oversight and public awareness, the Supreme Court has also directed the Union Government to develop a national dashboard within three months. This dashboard is intended to serve as a repository for information on actions taken against misleading advertisements, providing a transparent overview of enforcement efforts across the country.

Recognizing the importance of public education in combating misleading health claims, the apex court has directed its registry to share the order with the National Legal Services Authority (NALSA). NALSA is tasked with incorporating awareness programs on the Drugs and Magic Remedies Act into its outreach initiatives, aimed at educating the masses about the dangers of deceptive medical advertisements and their legal rights.

Background: IMA Petition and Patanjali Case

The Supreme Court's assertive stance on misleading advertisements stems from a petition filed in 2022 by the Indian Medical Association (IMA). The IMA raised serious concerns about a "smear campaign" allegedly orchestrated by Patanjali and yoga guru Ramdev against the COVID-19 vaccination drive and modern systems of medicine. While the current directives are broader in scope, targeting all forms of misleading medical advertising, the context of the IMA's petition underscores the gravity of the issue and the potential for misinformation to undermine public health initiatives.

The Court had previously, on May 7, 2024, taken steps to tighten advertising regulations by directing that a self-declaration be obtained from advertisers before any advertisement is issued. This requirement, modeled on the Cable Television Networks Rules, 1994, is intended to add a layer of accountability and pre-vetting to advertising content.

Legal and Practical Implications

The Supreme Court's latest directives carry significant legal and practical implications for various stakeholders:

For State Governments and Union Territories:

Resource Allocation: States and UTs will need to allocate resources to establish and publicize the grievance redressal mechanisms within the stipulated two-month timeframe. This includes setting up infrastructure, potentially staffing call centers or email complaint handling teams, and conducting public awareness campaigns.

Training and Sensitization: Police forces and designated officers will require training and sensitization on the Drugs and Magic Remedies Act, 1954, to effectively identify, investigate, and act upon violations. This may necessitate incorporating relevant modules into police training academies and conducting workshops for designated officers.

Enforcement Challenges: Effective enforcement of the Act will require proactive monitoring of advertisements across various media platforms, efficient processing of complaints, and timely action against violators. States will need to develop robust systems to manage the anticipated influx of complaints and ensure accountability in enforcement actions.

For Advertisers and the Healthcare Industry:

Increased Scrutiny: Advertisers of medical products and services will face heightened scrutiny of their promotional materials. Claims made in advertisements will need to be meticulously substantiated and compliant with the Drugs and Magic Remedies Act and related regulations.

Pre-vetting and Compliance: The self-declaration requirement and the active grievance redressal mechanisms will likely necessitate a more cautious and compliant approach to advertising. Legal counsel will become crucial in reviewing advertising campaigns to ensure adherence to regulations and mitigate the risk of legal action.

Potential for Legal Action: The strengthened enforcement framework significantly increases the potential for legal action against advertisers found to be disseminating misleading information. This includes both criminal proceedings initiated by designated officers and potential civil suits from consumers who have suffered harm due to deceptive advertisements.

For Consumers:

Empowerment and Redressal: The establishment of accessible grievance redressal mechanisms empowers consumers to actively report misleading medical advertisements. This provides a formal channel for seeking redressal and contributing to a more transparent and trustworthy healthcare advertising landscape.

Protection from Misinformation: Effective implementation of the Supreme Court's directives is expected to significantly reduce the prevalence of misleading medical advertisements, thereby protecting consumers from potentially harmful and ineffective products or treatments promoted through deceptive claims.

Conclusion: A Strong Step Towards Regulatory Enforcement

The Supreme Court's proactive intervention marks a crucial step towards ensuring the effective implementation of the Drugs and Magic Remedies Act, 1954, and curbing the menace of misleading medical advertisements. By setting clear deadlines, mandating specific actions from state governments and the Union government, and emphasizing public awareness, the apex court has signaled its commitment to protecting public health and promoting ethical advertising practices within the healthcare sector. The legal community, particularly those advising healthcare clients and consumer protection groups, will be closely watching the implementation of these directives and their impact on the regulatory landscape. The next few months will be critical in assessing the responsiveness of state governments and the effectiveness of the newly mandated grievance redressal mechanisms in achieving the Supreme Court's objective of a more transparent and responsible medical advertising environment.